Innoviva Inc (INVA) |
|
12.62 -0.11 (-0.86%)
|
01-21 01:04 |
|
Open: |
12.7 |
Pre. Close: |
12.73 |
|
High:
|
12.84 |
Low:
|
12.57 |
|
Volume:
|
884,507 |
Market Cap:
|
1,280M |
|
|
|
|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.87 - 12.933 |
12.933 - 12.985 |
|
Low:
|
12.394 - 12.481 |
12.481 - 12.551 |
|
Close:
|
12.5 - 12.63 |
12.63 - 12.735 |
|
Technical analysis |
as of: 2021-01-20 4:48:45 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.25 One year: 17.82 |
| Support: |
Support1: 11.41  Support2: 10.39 |
| Resistance: |
Resistance1: 13.06 Resistance2: 15.25 |
| Pivot: |
12.56 |
| Moving Average: |
MA(5): 12.64 MA(20): 12.45
MA(100): 11.13 MA(250): 12.48 |
| MACD: |
MACD(12,26): 0.34 Signal(9): 0.38 |
| Stochastic oscillator: |
%K(14,3): 63.05 %D(3): 65.76 |
| RSI: |
RSI(14): 58.95 |
| 52-week: |
High: 15.62 Low: 7.58 Change(%): -12.2 |
| Average Vol(K): |
3-Month: 70868 10-Days: 50218 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.INVA has closed below upper band by 42.9%. Bollinger Bands are 46% narrower than normal. The narrow width of the bands suggests low volatility as compared to INVA's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sun, 17 Jan 2021
Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 1/17/2021 - Nasdaq
Sat, 16 Jan 2021
Innoviva, Inc. (NASDAQ:INVA) Expected to Post Earnings of $0.41 Per Share - MarketBeat
Thu, 14 Jan 2021
Innoviva Inc. (INVA) Soars 5.15% on January 14 - Equities.com
Tue, 05 Jan 2021
Innoviva (NASDAQ:INVA) Upgraded at TheStreet - MarketBeat
Mon, 04 Jan 2021
Top Ranked Value Stocks to Buy for January 4th - Nasdaq
Mon, 04 Jan 2021
Is Innoviva (NASDAQ:INVA) A Risky Investment? - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
101 |
| Shares Float (M) |
54 |
|
% Held by Insiders
|
31.97 |
|
% Held by Institutions
|
75.88 |
|
Shares Short (K)
|
9,360 |
|
Shares Short P. Month (K)
|
9,410 |
Stock Financials |
|
EPS
|
1.910 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
4.790 |
|
Profit Margin
|
67.16 |
|
Operating Margin
|
96.18 |
|
Return on Assets (ttm)
|
24.2 |
|
Return on Equity (ttm)
|
67.6 |
|
Qtrly Rev. Growth
|
34.9 |
|
Gross Profit (p.s.)
|
2.574 |
|
Sales Per Share
|
3.179 |
|
EBITDA (p.s.)
|
3.058 |
|
Qtrly Earnings Growth
|
-29.10 |
|
Operating Cash Flow (M)
|
295 |
|
Levered Free Cash Flow (M)
|
183 |
Stock Valuations |
|
PE Ratio
|
6.61 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.63 |
|
Price to Sales
|
3.97 |
|
Price to Cash Flow
|
4.34 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2015-09-29 |
|
Ex-Dividend Date
|
2015-09-07 |
|
7 Binary Options
|
|
Your Ad Here
|
|
